Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table.<\/p>
<\/p>
<\/strong><\/p> <\/p> Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:<\/p> <\/p> 3.1.1 Adrenoceptor agonists<\/p> <\/p> 3.1.2 Antimuscarinic bronchodilators<\/p> <\/p> 3.1.3 Theophylline<\/p> <\/p> 3.2 Corticosteroids<\/p> <\/p> 3.3.1 Cromoglicate and related therapy<\/p> <\/p> 3.3.2 Leukotriene receptor antagonists<\/p> <\/p> 3.4.2 Allergen immunotherapy (omalizumab only)<\/p> <\/p> <\/p> <\/p> Cost of drugs for the treatment of asthma, England1<\/sup><\/p><\/td><\/tr> Drug name<\/p><\/td> Primary Care (£ millions)<\/p><\/td> Secondary Care (£ millions)<\/p><\/td><\/tr> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td> 2009<\/p><\/td> 2010<\/p><\/td> 2011<\/p><\/td> 2012<\/p><\/td> 2013<\/p><\/td><\/tr> Aclidinium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.02<\/p><\/td> 1.62<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.03<\/p><\/td><\/tr> Aminophylline<\/p><\/td> 1.25<\/p><\/td> 1.18<\/p><\/td> 1.12<\/p><\/td> 1.08<\/p><\/td> 1.05<\/p><\/td> 0.30<\/p><\/td> 0.29<\/p><\/td> 0.21<\/p><\/td> 0.23<\/p><\/td> 0.22<\/p><\/td><\/tr> Beclometasone Dipropionate<\/p><\/td> 84.26<\/p><\/td> 87.72<\/p><\/td> 90.30<\/p><\/td> 97.56<\/p><\/td> 102.39<\/p><\/td> 1.62<\/p><\/td> 1.53<\/p><\/td> 1.41<\/p><\/td> 1.49<\/p><\/td> 1.42<\/p><\/td><\/tr> Budesonide<\/p><\/td> 140.35<\/p><\/td> 149.03<\/p><\/td> 158.82<\/p><\/td> 169.14<\/p><\/td> 177.00<\/p><\/td> 1.29<\/p><\/td> 1.14<\/p><\/td> 1.14<\/p><\/td> 1.27<\/p><\/td> 1.41<\/p><\/td><\/tr> Budesonide/ Formoterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 2.75<\/p><\/td> 2.94<\/p><\/td> 2.89<\/p><\/td> 3.10<\/p><\/td> 3.29<\/p><\/td><\/tr> Ciclesonide<\/p><\/td> 0.84<\/p><\/td> 0.95<\/p><\/td> 1.03<\/p><\/td> 1.12<\/p><\/td> 1.25<\/p><\/td> 0.01<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.02<\/p><\/td> 0.03<\/p><\/td><\/tr> Fluticasone<\/p><\/td> 366.24<\/p><\/td> 380.56<\/p><\/td> 387.89<\/p><\/td> 392.95<\/p><\/td> 396.10<\/p><\/td> 1.00<\/p><\/td> 0.93<\/p><\/td> 0.91<\/p><\/td> 1.00<\/p><\/td> 0.99<\/p><\/td><\/tr> Fluticasone/ Salmeterol<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 11.46<\/p><\/td> 11.56<\/p><\/td> 10.69<\/p><\/td> 10.82<\/p><\/td> 10.48<\/p><\/td><\/tr> Formoterol Fumarate<\/p><\/td> 5.18<\/p><\/td> 4.87<\/p><\/td> 4.68<\/p><\/td> 4.85<\/p><\/td> 4.93<\/p><\/td> 0.10<\/p><\/td> 0.08<\/p><\/td> 0.07<\/p><\/td> 0.06<\/p><\/td> 0.06<\/p><\/td><\/tr> Glycopyrronium Bromide<\/p><\/td> -<\/p><\/td> -<\/p><\/td> -<\/p><\/td> 0.01<\/p><\/td> 2.30<\/p><\/td> 0.58<\/p><\/td> 0.62<\/p><\/td> 0.70<\/p><\/td> 0.79<\/p><\/td> 1.00<\/p><\/td><\/tr> Indacaterol Maleate<\/p><\/td> -<\/p><\/td> 0.04<\/p><\/td> 0.30<\/p><\/td> 0.92<\/p><\/td> 1.47<\/p><\/td> -<\/p><\/td> 0.00<\/p><\/td> 0.00<\/p><\/td> 0.02<\/p><\/td> 0.04<\/p><\/td><\/tr> Ipratropium Bromide<\/p><\/td> 16.15<\/p><\/td> 15.02<\/p><\/td> 13.74<\/p><\/td> 10.32<\/p><\/td> 8.61<\/p><\/td> 2.74<\/p><\/td> 2.84<\/p><\/td> 2.59<\/p><\/td> 2.65<\/p><\/td> 2.70<\/p><\/td><\/tr> Mometasone Furoate<\/p><\/td> 0.36<\/p><\/td> 0.31<\/p><\/td> 0.26<\/p><\/td> 0.23<\/p><\/td> 0.21<\/p><\/td> 0.76<\/p><\/td> 0.71<\/p><\/td> 0.61<\/p><\/td> 0.63<\/p><\/td> 0.67<\/p><\/td><\/tr> Montelukast<\/p><\/td> 38.91<\/p><\/td> 43.01<\/p><\/td> 46.96<\/p><\/td> 51.71<\/p><\/td> 31.31<\/p><\/td> 0.98<\/p><\/td> 1.02<\/p><\/td> 1.03<\/p><\/td> 1.16<\/p><\/td> 0.81<\/p><\/td><\/tr> Omalizumab<\/p><\/td> 0.00<\/p><\/td> 0.01<\/p><\/td> 0.03<\/p><\/td> 0.15<\/p><\/td> 0.12<\/p><\/td> 5.97<\/p><\/td> 9.22<\/p><\/td> 12.16<\/p><\/td> 14.65<\/p><\/td> 17.86<\/p><\/td><\/tr> Salbutamol<\/p><\/td> 83.15<\/p><\/td> 82.64<\/p><\/td> 60.58<\/p><\/td> 60.37<\/p><\/td> 59.95<\/p><\/td> 3.78<\/p><\/td> 3.77<\/p><\/td> 3.36<\/p><\/td> 3.38<\/p><\/td> 3.29<\/p><\/td><\/tr> Salmeterol<\/p><\/td> 48.80<\/p><\/td> 45.16<\/p><\/td> 41.87<\/p><\/td> 36.72<\/p><\/td> 34.04<\/p><\/td> 0.87<\/p><\/td> 0.74<\/p><\/td> 0.59<\/p><\/td> 0.53<\/p><\/td> 0.47<\/p><\/td><\/tr> Terbutaline Sulphate<\/p><\/td> 8.61<\/p><\/td> 8.20<\/p><\/td> 7.61<\/p><\/td> 7.43<\/p><\/td> 7.18<\/p><\/td> 0.18<\/p><\/td> 0.16<\/p><\/td> 0.14<\/p><\/td> 0.14<\/p><\/td> 0.15<\/p><\/td><\/tr> Theophylline<\/p><\/td> 2.18<\/p><\/td> 2.17<\/p><\/td> 2.15<\/p><\/td> 2.22<\/p><\/td> 2.26<\/p><\/td> 0.12<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td> 0.11<\/p><\/td><\/tr> Tiotropium<\/p><\/td> 113.61<\/p><\/td> 129.98<\/p><\/td> 149.81<\/p><\/td> 169.35<\/p><\/td> 185.24<\/p><\/td> 5.69<\/p><\/td> 6.03<\/p><\/td> 6.22<\/p><\/td> 6.64<\/p><\/td> 6.87<\/p><\/td><\/tr> Zafirlukast<\/p><\/td> 0.79<\/p><\/td> 0.71<\/p><\/td> 0.71<\/p><\/td> 0.70<\/p><\/td> 0.69<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td> 0.01<\/p><\/td><\/tr> Other drugs2<\/sup><\/p><\/td> 0.90<\/p><\/td> 0.79<\/p><\/td> 0.66<\/p><\/td> 0.62<\/p><\/td> 0.60<\/p><\/td> 0.04<\/p><\/td> 0.07<\/p><\/td> 0.15<\/p><\/td> 0.26<\/p><\/td> 0.46<\/p><\/td><\/tr> Total<\/p><\/td> 911.6<\/p><\/td> 952.3<\/p><\/td> 968.5<\/p><\/td> 1,007.5<\/p><\/td> 1,018.3<\/p><\/td> 40.3<\/p><\/td> 43.8<\/p><\/td> 45.0<\/p><\/td> 49.0<\/p><\/td> 52.4<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> 1 <\/sup>Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.<\/p> <\/p> 2<\/sup> Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate.<\/p> <\/p> Source:<\/p> <\/p> Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)<\/p> <\/p> Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)<\/p> <\/p> <\/p> <\/p> Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:13:01.0657405Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211846"}
, {"_about" : "http://data.parliament.uk/resources/100877", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100877/answer", "answerText" : {"_value" : " The following table sets out expenditure on asthma from 2008-09 to 2012-131 <\/sup><\/p> <\/p> <\/p> <\/p> <\/p> <\/p> Expenditure (£ billion)<\/p><\/td><\/tr> 2008-09<\/p><\/td> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td><\/tr> 0.87<\/p><\/td> 0.91<\/p><\/td> 0.99<\/p><\/td> 1.01<\/p><\/td> 1.05<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> <\/p> <\/p> 1<\/sup> Aggregate primary care trust (PCT) expenditure on own population from programme budgeting collection. Programme budgeting is an annual collection of expenditure on healthcare conditions by NHS Commissioners. Programme budgeting figures are only estimates.<\/p> <\/p> <\/p> <\/p> It should be noted that this does not include expenditure on primary care appointments which is included as a separate category. Other areas of expenditure such as Outpatients and Community Care cannot always be allocated to sub-categories so some expenditure on asthma may be included in \u2018Problems of the Respiratory System \u2013 Other\u2019 or \u2018Other - Miscellaneous\u2019.<\/p> <\/p> <\/strong><\/p> <\/p> Further notes on interpretation of data:<\/p> <\/p> - Expenditure data are calculated from programme budgeting returns for 2003-04 to 2012-13. Programme budgeting returns are based on a subset of PCT accounts data and represent a subset of overall NHS expenditure data.<\/p> <\/p> <\/p> <\/p> - Calculating programme budgeting data is complex and not all healthcare activity or services can be classified directly to a programme budgeting category or care setting. When it is not possible to reasonably estimate a programme budgeting category, expenditure is classified as \u2018Other\u2019. Expenditure on General Medical Services and Personal Medical Services cannot be reasonably estimated at disease specific level, and is separately identified as a subcategory of \u2018Other\u2019 expenditure.<\/p> <\/p> <\/p> <\/p> - The allocation of expenditure to programme budgeting subcategories is not always straightforward, and subcategory level data should therefore be used with caution.<\/p> <\/p> <\/p> <\/p> - In order to improve data quality, continual refinements have been made to the programme budgeting data calculation methodology since the first collection in 2003-04. The underlying data which support programme budgeting data are also subject to yearly changes. Programme budgeting data cannot be used to analyse changes in investment in specific service areas between years. Users of the data should note that significant changes to the data calculation methodology were introduced in 2010-11.<\/p> <\/p> <\/p> <\/p> - Figures for years 2003-04 to 2009-10 are calculated using provider costs as a basis. Figures for 2010-11 to 2012-13 are calculated using price paid for specific activities and services purchased from healthcare providers. PCTs follow standard guidance, procedures and mappings when calculating programme budgeting data.<\/p> <\/p> <\/p> <\/p> - PCT figures used to calculate 2010-11 data differ from those previously published in the 2010-11 programme budgeting benchmarking spreadsheet. This is due to the correction of errors identified for five PCTs for this year.<\/p> <\/p> <\/p> <\/p> - Aggregate PCT data supersede previously published England level programme budgeting data. England level data incorporated estimates of expenditure on healthcare conditions for the Department of Health, strategic health authorities and special health authorities. England level data is no longer published this data as aggregate PCT figures provide a more accurate and meaningful representation of the breakdown of NHS expenditure by healthcare condition.<\/p> <\/p> <\/p> <\/p> - For 2003-04, figures are based on PCT net expenditure. For 2004-05 onwards, figures are based on PCT spend on own population. This is calculated by adjusting net expenditure to add back expenditure funded from sources outside the NHS and to deduct expenditure on other PCT populations incurred through lead commissioning arrangements.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1439", "label" : {"_value" : "Biography information for Norman Lamb"}
}
, "answeringMemberConstituency" : {"_value" : "North Norfolk"}
, "answeringMemberPrinted" : {"_value" : "Norman Lamb"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T15:06:29.0052916Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of treating asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211847"}
, {"_about" : "http://data.parliament.uk/resources/100885", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100885/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100885/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:29.113Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211885"}
, {"_about" : "http://data.parliament.uk/resources/100887", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100887/answer", "answerText" : {"_value" : " The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships.<\/p> <\/p> <\/p> <\/p> £ million<\/em><\/p> <\/p> 2009-10<\/p><\/td> 2010-11<\/p><\/td> 2011-12<\/p><\/td> 2012-13<\/p><\/td> 2013-14<\/p><\/td><\/tr> Asthma<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.3<\/p><\/td> 1.5<\/p><\/td> 0.8<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 2.6<\/p><\/td> 3.4<\/p><\/td> 2.4<\/p><\/td> 3.4<\/p><\/td> 3.8<\/p><\/td><\/tr> Total<\/p><\/td> Motor Neurone Research<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 7.0<\/p><\/td> 7.5<\/p><\/td> 4.2<\/p><\/td> 4.1<\/p><\/td> 3.6<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.2<\/p><\/td> 0.2<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.1<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 0.7<\/p><\/td> 0.5<\/p><\/td><\/tr> Total<\/p><\/td> 7.3<\/p><\/td> 7.8<\/p><\/td> 5.0<\/p><\/td> 5.5<\/p><\/td> 5.1<\/p><\/td><\/tr> Osteoporosis<\/p><\/td><\/tr> Medical Research Council<\/p><\/td> 6.2<\/p><\/td> 5.4<\/p><\/td> 5.1<\/p><\/td> 4.6<\/p><\/td> 5.9<\/p><\/td><\/tr> Other Research Councils and Innovate UK<\/p><\/td> 0.0<\/p><\/td> 0.0<\/p><\/td> 0.1<\/p><\/td> 0.4<\/p><\/td> 1.0<\/p><\/td><\/tr> National Institute for Health Research<\/p><\/td> 0.3<\/p><\/td> 0.7<\/p><\/td> 0.8<\/p><\/td> 1.3<\/p><\/td> 1.8<\/p><\/td><\/tr> Total<\/p><\/td> 6.5<\/p><\/td> 6.1<\/p><\/td> 6.0<\/p><\/td> 6.3<\/p><\/td> 8.7<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma.<\/p> <\/p> <\/p> <\/p> Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure.<\/p> <\/p> <\/p> <\/p> Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2014-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "true", "_datatype" : "boolean"}
, "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/100887/answer/previousversion/25123", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
}
, "questionFirstAnswered" : [{"_value" : "2014-10-29T17:12:28.3318918Z", "_datatype" : "dateTime"}
], "questionFirstMinisteriallyCorrected" : [{"_value" : "2014-11-13T10:22:56.0372213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2014-10-24", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how much public funding was allocated to research into asthma in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4026", "label" : {"_value" : "Biography information for Liz Kendall"}
}
, "tablingMemberConstituency" : {"_value" : "Leicester West"}
, "tablingMemberPrinted" : [{"_value" : "Liz Kendall"}
], "uin" : "211918"}
, {"_about" : "http://data.parliament.uk/resources/100708", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/100708/answer", "answerText" : {"_value" : " The Public Health Outcomes Framework launched in 2012 includes an indicator on preventable sight loss which tracks sight loss due to the three main causes: age related macular degeneration, diabetic retinopathy and glaucoma. Data has been published for 2010-11, 2011-12 and 2012-13 and the number of people aged 12 years and above who lost their eye sight from diabetes is shown in the following table.<\/p> <\/p> <\/p> <\/p> A sight loss indicator per 100,000 people for England for each of the three years is also included. The source of the data is Public Health England\u2019s outcomes website and the links to the data are below the table.<\/p> <\/p> <\/p> <\/p> Indicator<\/p><\/td> Year<\/p><\/td> Indicator value per 100,000 population<\/p><\/td> Number of people who lost their eye sight from diabetes<\/p><\/td><\/tr> 4.12iii - Preventable sight loss - diabetic eye disease<\/p><\/td> 2010-11<\/p><\/td> 3.6<\/p><\/td> 1,611<\/p><\/td><\/tr> 4.12iii - Preventable sight loss - diabetic eye disease<\/p><\/td> 2011-12<\/p><\/td> 3.8<\/p><\/td> 1,755<\/p><\/td><\/tr> 4.12iii - Preventable sight loss - diabetic eye disease<\/p><\/td> 2012-13<\/p><\/td> 3.5<\/p><\/td> 1,592<\/p><\/td><\/tr><\/tbody><\/table> <\/p> <\/p> <\/p> Source:<\/em><\/p> <\/p> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr> <\/td> 22.2 <\/del>6.6<\/ins><\/p><\/td>17.5 <\/del>5.3<\/ins><\/p><\/td>17.2<\/del> 4.5<\/ins><\/p><\/td>19.4<\/del> 3.6<\/ins><\/p><\/td>18.8<\/del> 5.4<\/ins><\/p><\/td><\/tr>24.8<\/del> 9.2<\/ins><\/p><\/td>21.0<\/del> 8.8<\/ins><\/p><\/td>19.9<\/del> 7.2<\/ins><\/p><\/td>24.3 <\/del>8.5<\/ins><\/p><\/td>23.4<\/del> 10.0<\/ins><\/p><\/td><\/tr>